KFAS
PRCT icon

Keating Financial Advisory Services’s Procept Biorobotics PRCT Stock Holding History

Keating Financial Advisory Services’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$25 – 2687
2026
Q1 		$25 Buy
+1
New +$28 ﹤0.01% 2493

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Keating Financial Advisory Services's PRCT Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 1 share — an estimated $25 sold.

Keating Financial Advisory Services first reported a position in PRCT in Q1 2026 and held it in 1 quarter. The position peaked at $25 in Q1 2026. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 1 Procept Biorobotics share in Q2 2026, an estimated $25.
  • Keating Financial Advisory Services first reported a position in Procept Biorobotics in Q1 2026 and held it in 1 quarter.
  • Keating Financial Advisory Services's Procept Biorobotics position peaked at $25 in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.